KRCA-0713 is an ALK inhibitor with anti-ALK activity. KRCA-0713 showed promising anti-ALK activity in enzyme and cell-based experiments. KRCA-0713 was shown to effectively inhibit ALK-driven tumor growth in H3122 xenograft model studies, similar to the effect of ceritinib[1].
Molekulargewicht:
530.08
CAS Nummer:
[1884321-89-4]
Formel:
C26H32ClN5O3S
Target-Kategorie:
Anaplastic lymphoma kinase (ALK)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten